“…Immunotoxin‐based anti‐PD‐L1 mAb is considered to be an effective tumor treatment method in theory, because: (i) the immune checkpoint protein PD‐L1 is broadly expressed in many cancers, 9,20,26,27 which is spectral in treatment; (ii) its expression is limited in tumor area but not in normal cells, the treatment is mainly aimed at tumor tissue, which makes PD‐L1‐specific treatment more accurate, and its side‐effects limited; (iii) ELISA assay showed that PD‐L1, as a transmembrane protein, was not released from the constitutively expressing PD‐L1 cell membrane; and (iv) the key is that PD‐L1 on tumor cells is glycosylated, so when anti‐PD‐L1 mAb is combined in the glycosylated domain, it will produce internalization, 28 which provides a good antitumor basis for IT‐based treatment 28,29 . At present, PD‐L1‐specific treatment, such as PDL1‐Dox 30 and PD‐L1‐AuNP‐DOX 31 in the form of an Ab‐drug conjugate, have shown some promising results. However, few studies focus on the generation of PD‐L1 by ITs.…”